Biopharmaceutical company MediciNova has plans to study its investigational drug, ibudilast (MN-166), to treat acute respiratory distress syndrome (ARDS) associated with Covid-19.
Ibudilast is an oral, small-molecule inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterase (PDE) -4 and -10. It inhibits pro-inflammatory cytokines and promotes neurotrophic factors.
In previous studies, the drug candidate led to a significant decrease in serum MIF level.
The company also added that ibudilast showed anti-neuroinflammatory and neuroprotective properties in preclinical and clinical studies for neurological diseases, including amyotrophic lateral sclerosis and progressive multiple sclerosis.
MediciNova president and CEO Yuichi Iwaki said: “We are very pleased to announce initiation of a clinical trial of MN-166 in ARDS caused by Covid-19.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“This study also will allow investigators to determine the optimal dose and route of administration in these very critical patients.”
MediciNova expects that the drug candidate could mitigate the hyper-inflammation and ARDS found in severe cases of Covid-19 infection.
The planned study of ibudilast in Covid-19 patients will be performed by Yale’s Advanced Therapies Group.
Yale’s Advanced Therapies Group co-director Richard Bucala said: “This study is especially gratifying because MN-166’s inhibition of MIF activity was discovered in Yale Pharmacology by Elias Lolis.
“We believe MN-166 has the potential to reduce the mortality of Covid-19 by limiting the hyper-inflammation and ARDS associated with severe cases.”
In a separate development, Yale University said that its lung fibrosis drug candidate sobetirome may possess the potential to treat some life-threatening effects of Covid-19.
Sobetirome works by healing scarring and improving cell function in lungs. In a recent study, the drug also demonstrated promise in preventing and treating ARDS.
Researchers at the university are making preparations to study sobetirome in trials.
